Please login to the form below

Not currently logged in

Cell Therapeutics closes Zevalin buyout

Cell Therapeutics completes the USD 30m purchase of Biogen Idec's cancer drug, Zevalin

US-based biotechnology company Cell Therapeutics has completed the USD 30m purchase of Biogen Idec's cancer drug, Zevalin (90Y-ibritumomab tiuxetan).

In August 2007, Cell said it would buy US marketing, sales and development rights for the drug with a USD 10m upfront payment.

The deal also includes USD 20m in milestone payments when the drug is approved as an initial treatment for non-Hodgkin's lymphoma. It is already approved to treat patients who have relapsed after prior therapy.

Cell will pay royalties to Biogen based on Zevalin's net sales until at least December 2015. The company will pay royalties and share clinical trial costs with Bayer Schering, if studies are conducted outside the US, where Bayer Schering sells Zevalin.

On 27 December, Cell's shares rose USD 0.06 cents, or 3.2 per cent, to reach USD 1.91 in morning trading. Biogen's shares fell USD 0.33 to rest at USD 59.01.

FY06 sales of Zevalin were USD 16.4m.

2nd January 2008


Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked